PharmaShots | Incisive News in 3 Shots

Subscribe Now

tumor diseases

Samsung Bioepis' Aybintio (SB8- biosimilar- bevacizumab) Receives the EC's Approval for Launch in EU

Samsung Bioepis' Aybintio (SB8- biosimilar- bevacizumab) Receives the EC's Approval for Launch in EU

August 21, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us